# Recombinant Human VAP-1/AOC3 Protein (His Tag)

Catalog Number: PKSH032744



Note: Centrifuge before opening to ensure complete recovery of vial contents.

				ption		
	06		TO T	m	11	$\mathbf{n}$
v					ш	w

 Species
 Human

 Mol\_Mass
 82.6 kDa

 Accession
 O16853

**Bio-activity** Not validated for activity

# **Properties**

**Purity** > 95 % as determined by reducing SDS-PAGE.

**Endotoxin**  $\leq 1.0 \text{ EU per } \mu \text{g of the protein as determined by the LAL method.}$  **Storage** Storage Stor


**Shipping** This product is provided as liquid. It is shipped at frozen temperature with blue ice/gel

packs. Upon receipt, store it immediately at < - 20°C.

Formulation Supplied as a 0.2 μm filtered solution of 20mM Tris-HCl, 500mM NaCl, pH 8.0.

**Reconstitution** Not Applicable

### Data



> 95 % as determined by reducing SDS-PAGE.

# Background

Vascular adhesion protein-1(VAP-1) is a copper amine oxidase with a topaquinone cofactor.VAP-1 is a type II integral membrane protein; but a soluble form of the enzyme is present in human serum; and its level increases in diabetes and some inflammatory liver diseases. VAP-1 catalyzes the oxidative deamination of small primary amines such as methylamine; benzylamine; and aminoacetone in a reaction that produces an aldehyde; ammonia; and H2O2. VAP-1 vascular expression is regulated at sites of inflammation through its release from intracellular granules in which the protein is stored. The adhesive function of VAP-1 has been demonstrated in studies showing that the protein is important for the adherence of certain lymphocyte subtypes to inflamed endothelial tissues. VAP-1 mediated adhesion is involved in the process of leukocyte extravasation; an important feature of inflammatory responses. VAP-1 is considered to be a therapeutic target for diabetes; oxidative stress; and inflammatory diseases.

# For Research Use Only